- Home
- ACTG vs MNPR Comparison
ACTG vs MNPR Comparison
Compare ACTG & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACTG | MNPR |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.9M | 372.9M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ACTG | MNPR |
|---|---|---|
| Price | $4.16 | $55.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $101.42 |
| AVG Volume (30 Days) | ★ 229.9K | 191.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $12,004,000.00 | N/A |
| Revenue This Year | $127.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.70 | $26.06 |
| 52 Week High | $4.32 | $105.00 |
Technical Indicators
Market Signals| Indicator | ACTG | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.20 | 44.22 |
| Support Level | $3.54 | $51.11 |
| Resistance Level | $4.29 | $61.30 |
| Average True Range (ATR) | 0.13 | 3.55 |
| MACD | -0.00 | 0.38 |
| Stochastic Oscillator | 57.14 | 49.29 |
Price Performance
Historical ComparisonAbout ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.